Tech Company Financing Transactions
BiPER Therapeutics Funding Round
Bpifrance and Wiseed participated in a $1.3 million funding round for BiPER Therapeutics. This venture round closed on 2/14/2023.
Transaction Overview
Company Name
Announced On
2/14/2023
Transaction Type
Venture Equity
Amount
$1,329,000
Round
Undisclosed
Proceeds Purpose
The funds will allow BiPER to work, over the next 15 months, on the preclinical development of BPR001 for the treatment of gastrointestinal cancers, and bring it to the Clinical Trial Application (CTA)/Investigational New Drug (IND) stages, with gastric cancer as the primary indication. It will also enable the company to advance its R&D programs in first-in-class Endoplasmic Reticulum (ER) stress inducers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11, rue de l'académie
Strasbourg, 67000
FR
Strasbourg, 67000
FR
Phone
Undisclosed
Website
Email Address
Overview
BiPER Therapeutics is a biotech company founded in 2021 to develop and commercialize novel therapeutics. We are developing a first-in-class pipeline of small molecules targeting the metabolism of cancer cells to treat advanced cancers with high unmet medical needs
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mehdi CHELBI
Chief Scientific Officer
Michaël CEREZO
Browse more venture capital transactions:
Prev: 2/14/2023: Dentity venture capital transaction
Next: 2/14/2023: Betty venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs